On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the November 2021 CRG meeting.

Actions in this consultation include:

  • Insulin aspart Sanofi (Trurapi) to be added to formulary as a GREEN drug and first line option for rapid acting insulin.
  • Haloperidol 500 microgram tablets to be DNP (criterion 2)
  • Berotralstat for hereditary angioedema to be added to the RAG list as a RED drug
  • Casirivimab/imdevimab (Ronapreve)® to be added to formulary as a RED drug, with link to NG191

To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Thursday 23rd December 2021.